Study S001732

A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02098395
Acronym: ADJUNCT TWO™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 835
Start: 2014-05
Primary completion: 2015-04
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2012-005778-74; OTHER:U1111-1138-0619; REGISTRY:NL47705.060.14; REGISTRY:REec-2014-0884

Registered primary outcomes

Change From Baseline in Glycosylated Haemoglobin (HbA1c) [Week 0, Week 26]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0019604	Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies. Shah VN, Journal of diabetes science and technology	2025	Randomized trial	PMID 39717993 DOI	cites ClinicalTrials.gov:NCT02098395; registry reference DERIVED:39717993
R0008931	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Dejgaard TF, Diabetes, obesity & metabolism	2021	Randomized trial	PMID 34463425 DOI	cites ClinicalTrials.gov:NCT02098395; registry reference DERIVED:34463425
R0046904	675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two Thomas Fremming Dejgaard, Diabetes	2021	Randomized trial	DOI	cites ClinicalTrials.gov:NCT02098395
R0025614	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Ahrén B, Diabetes care	2016	Randomized trial	PMID 27493132 DOI	cites ClinicalTrials.gov:NCT02098395; registry reference RESULT:27493132